Applied Therapeutics, Inc. (APLT): Price and Financial Metrics


Applied Therapeutics, Inc. (APLT)

Today's Latest Price: $20.41 USD

0.14 (-0.68%)

Updated Jan 27 4:00pm

Add APLT to Watchlist
Sign Up

Overall POWR Rating

Sign Up to See Ratings...FREE!

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

APLT Stock Price Chart Interactive Chart >

Price chart for APLT

APLT Price/Volume Stats

Current price $20.41 52-week high $57.39
Prev. close $20.55 52-week low $13.58
Day low $19.68 Volume 84,266
Day high $20.96 Avg. volume 84,465
50-day MA $21.46 Dividend yield N/A
200-day MA $28.52 Market Cap 458.98M

Applied Therapeutics, Inc. (APLT) Company Bio

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY

Most Popular Stories View All

• #1 Ingredient for Picking the Best Stocks

• Is General Motors the Next Tesla?

• 2 Stocks That Could be Acquisition Targets in 2021: DropBox, Yelp

• 3 "Strong Buy" Tech Stocks with PE Ratios Under 15

• Forget Alibaba, Buy These 4 Asian E-Commerce Stocks Instead

View All Top Stories

APLT Latest News Stream

Event/Time News Detail
Loading, please wait...
View All APLT News

APLT Latest Social Stream

Loading social stream, please wait...

View Full APLT Social Stream

Latest APLT News From Around the Web

Below are the latest news stories about Applied Therapeutics Inc that investors may wish to consider to help them evaluate APLT as an investment opportunity.

Applied Therapeutics And The Murky World Of Biopharma Development

Applied Therapeutics (APLT) has two pivotal trials running in Galactosemia and Diabetic cardiomyopathy for pipeline assets AT-007 and AT-001 respectively. The first one has completed the adults study and pediatric study is ongoing; NDA is expected by Q3 2021. The second one will have topline data by 2022. In June,...

Avisol Capital Partners on Seeking Alpha | January 19, 2021

Applied Therapeutics to be Added to NASDAQ Biotechnology Index

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). The addition to the NBI will become effective prior to market open on Monday, December 21, 2020.The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked annually. All securities in the index...

Yahoo | December 15, 2020

Is Applied Therapeutics (APLT) a Smart Long-term Buy?

Baron Discovery Fund recently published its third-quarter commentary – a copy of which can be downloaded here. During the third quarter of 2020, the Baron Discovery Fund returned 18.83% (institutional shares). This was 11.67% better than the Russell 2000 Growth Index, the Fund’s primary benchmark index. You should check out Baron Discovery Fund’s top 5 […]

Yahoo | December 2, 2020

Applied Therapeutics Reports Third Quarter 2020 Financial Results

Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy (fatal heart disease affecting ~17%…

GlobeNewswire | November 12, 2020

Applied Therapeutics (NASDAQ:APLT) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Applied Therapeutics (NASDAQ:APLT) have been assigned an average rating of “Buy” from the ten ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have assigned a buy recommendation to the company. The average […]

Daily Political | October 21, 2020

Read More 'APLT' Stories Here

APLT Price Returns

1-mo -8.35%
3-mo 19.64%
6-mo -20.89%
1-year -59.04%
3-year N/A
5-year N/A
YTD -7.27%
2020 -19.32%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.825 seconds.